Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo
W Yu, K Gu, Z Yu, D Yuan, M He, N Ma, S Lai, J Zhao… - Cancer letters, 2013 - Elsevier
The multikinase-inhibition action of sorafenib provides strong rationales for its combination
use with radiotherapy. We investigated the in vitro and in vivo effect of sorafenib combined …
use with radiotherapy. We investigated the in vitro and in vivo effect of sorafenib combined …
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway
XF Dai, J Ding, RG Zhang, JH Ren… - International journal of …, 2013 - Taylor & Francis
Purpose: Sorafenib, an oral multikinase inhibitor, is the first agent that has demonstrated an
improved overall survival benefit in advanced hepatocellular carcinoma, setting a new …
improved overall survival benefit in advanced hepatocellular carcinoma, setting a new …
Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner
Q Li, Y Hu, M Xi, L He, L Zhao, M Liu - BMC cancer, 2012 - Springer
Background Hepatocellular carcinoma (HCC) has a high incidence and mortality.
Radiotherapy and sorafenib have proven effective for HCC. Here, we investigated whether …
Radiotherapy and sorafenib have proven effective for HCC. Here, we investigated whether …
Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
YB Kim, HC Jeung, I Jeong, K Lee… - Journal of radiation …, 2013 - academic.oup.com
Sorafenib, an orally available multikinase inhibitor, combined with radiation has shown
potential as an anticancer treatment in an in vitro and in vivo colon cancer model. In this …
potential as an anticancer treatment in an in vitro and in vivo colon cancer model. In this …
Cell cycle–dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
JP Plastaras, SH Kim, YY Liu, DT Dicker, JF Dorsey… - Cancer research, 2007 - AACR
The antineoplastic drug sorafenib (BAY 43-9006) is a multikinase inhibitor that targets the
serine-threonine kinase B-Raf as well as several tyrosine kinases. Given the numerous …
serine-threonine kinase B-Raf as well as several tyrosine kinases. Given the numerous …
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model
M Heravi, N Tomic, LH Liang, S Devic, J Holmes… - Anti-cancer …, 2012 - journals.lww.com
High expression of vascular endothelial growth factor (VEGF) in patients with breast cancer
has been associated with a poor prognosis, indicating that VEGF could be linked to the …
has been associated with a poor prognosis, indicating that VEGF could be linked to the …
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
Y Zhang, B Zhang, A Zhang, Y Zhao, J Zhao, J Liu… - Clinics, 2012 - SciELO Brasil
OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a
single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for …
single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for …
[HTML][HTML] Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model
Patients with unresectable hepatocellular carcinoma (HCC) usually have poor prognosis
because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are …
because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are …
Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo
YC Kuo, WC Lin, IT Chiang, YF Chang… - Biomedicine & …, 2012 - Elsevier
Over-expression of transcription factor nuclear factor-κB (NF-κB) in the residual tumor after
the treatment is often observed at the later period of cancer radiotherapy, results in tumor …
the treatment is often observed at the later period of cancer radiotherapy, results in tumor …
Sorafenib and radiotherapy association for hepatocellular carcinoma
N Girard, F Mornex - Cancer radiotherapie: journal de la Societe …, 2011 - europepmc.org
Conformal radiotherapy is a promising therapeutic strategy for hepatocellular carcinoma
(HCC), producing local control rates above 90% within the radiation beam. However …
(HCC), producing local control rates above 90% within the radiation beam. However …